Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) Aims to Modernize Classrooms in China via Strategic Partnership Agreement

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT), a producer, developer and operator of popular, augmented-reality, interactive, entertainment games and toys in China, recently entered a strategic agreement with Guangdong Family Periodicals Group. The two companies are partnering to develop innovative educational solutions that feature Blue Hat technologies (http://ibn.fm/TDA6M). A recent article discussing the company reads, “The partnership between the two entities is a result of technological advances over the past few years. The advent of 5G technology will make the widespread adoption of AR solutions a simpler task. This infrastructural development will enable innovators like Blue Hat to offer cutting-edge solutions to various types of consumers. The introduction of AR in Chinese schools is expected to give children an interactive platform that can enhance the learning experience and make it more entertaining. . . . Through the partnership, Blue Hat and Guangdong Family Periodicals Group will aim to create the so-called ‘AR Smart Kindergarten.’”

To view the full article, visit http://ibn.fm/akKqf

About Blue Hat Interactive Entertainment Technology

Headquartered in Xiamen, China, Blue Hat is a producer, developer and operator of augmented-reality, interactive entertainment games and toys, including interactive educational materials, mobile games and toys with mobile game features. For more information, visit the company’s website at www.BlueHatGroup.net.

NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://ibn.fm/BHAT

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Blue Hat Interactive Entertainment Technology BHAT, MissionIRNewsBreaks | Leave a comment

INmune Bio Inc. (NASDAQ: INMB) Announces Continuous Advancement of Clinical Program, New Strategic Appointment

  • The immunology company released its financial results for the second quarter of 2019 and also delivered an update on its clinical trials
  • The phase I trial of INmune Bio’s cancer treatment INB03 has delivered promising results in terms of safety and tolerability. The company will now be moving forward with the phase II of the trial
  • INmune Bio also announced the appointment of biotechnology executive Edgardo Baracchini as a new member of the board of directors

INmune Bio Inc.’s (NASDAQ: INMB) clinical program continues to advance, CEO RJ Tesi, M.D., noted during a presentation of the company’s 2019 second quarterly report. The business update, year-to-date, focused on financial results and on the advancement of the INB03 program (http://ibn.fm/shHin).

At the beginning of August, INmune Bio announced positive preliminary data from the INB03 phase I clinical trial. INB03 is a second-generation soluble tumor necrosis factor (sTNF) inhibitor, which the company believes alters the immunobiology of the tumor microenvironment to improve tumor killing in the body.

The phase I trial enlisted patients with advanced solid tumors. These volunteers received INB03 to determine the safety of the treatment in cancer patients. The medication was administered for an average of 74 days, and no adverse side effects were reported. INB03 was well tolerated.

As the company begins phase II testing, it hopes to establish the effectiveness of the medication in combination immunotherapy.

INmune Bio also announced that it expects to begin enlisting patients for a phase I trial of its other drug candidate, XPro1595, targeting Alzheimer’s disease. Patient enrollment is expected to begin in the second half of 2019.

Apart from announcing strategic developments, INmune Bio also presented its most important financial results for the second quarter. Net loss attributable to common stockholders for the second quarter was $0.4 million, in comparison to $6.2 million for the same quarter of 2018. Research and development expenditure remained unchanged at $0.3 million. The total research and development expenditure was $0.6 million, but it was partially offset by a $0.3 million Alzheimer’s Association grant.

As of June 30, INmune Bio had cash and cash equivalents of $9.4 million with no debt. In May 2019, INmune closed a private placement of nearly $4.7 million. As of August 9, INmune Bio has 10.8 million common and 13.9 million fully diluted shares outstanding.

INmune Bio has made another important announcement in line with its strategic development plans. On August 8, 2019, the company announced that Edgardo Baracchini, Ph.D., will be joining the INmune Bio team as a member of the board of directors (http://ibn.fm/zPl7l).

Barracchini brings extensive business development and deal-making experience to the board of directors, Tesi said. These are critical skills that are expected to benefit INmune Bio as it continues to advance its three main drug candidates through clinical trials, Tesi concluded.

Baracchini has over 25 years of experience in biotech business development. He has negotiated over 80 business transactions with multinational pharmaceutical firms, biotech businesses and prominent universities. His efforts have resulted in transactions estimated at over $5.3 billion.

“INmune Bio has very exciting clinical trials in cancer and Alzheimer’s disease,” Baracchini noted in a news release. “I am looking forward to working closely with its seasoned leadership team, each of whom have demonstrated their own track record of success.”

For more information, visit the company’s website at www.INmuneBio.com

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in INmune Bio Inc. INMB | Leave a comment

MissionIRNewsBreaks – The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Fulfils Initial Shipment to Ontario Cannabis Store

The Green Organic Dutchman Holdings (TSX: TGOD) (OTCQX: TGODF), a cannabis-focused research and development company, this morning announced the completion of its first shipment to the Ontario Cannabis Store. The shipment marks TGODF’s official entrance into Canada’s recreational market and provides consumers access to the company’s flagship strain, Unite Organic. The Ontario-grown dried flower will be available in select retail locations and at www.OCS.ca. “We are thrilled to introduce Unite Organic dried flower to Ontario adult consumers. Launched earlier this year with our Grower’s Circle, Unite Organic was highly praised by medical patients. Our small pilot confirmed that market demand for premium certified organic cannabis exceeds available supply,” The Green Organic Dutchman Holdings CEO Brian Athaide stated in the news release. “Today’s milestone gets us one step closer to achieving our vision of becoming the world’s leading brand for premium certified organic cannabis in both medical and recreational segments. We look forward to continuing to expand our distribution network as we ramp up production in the months ahead.”

To view the full press release, visit http://ibn.fm/JQmZP

About the Green Organic Dutchman Holdings Ltd.

The Green Organic Dutchman is a publicly traded, premium global organic cannabis company with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. TGOD also has organic hemp CBD oil operations in Canada, and through its wholly owned subsidiary HemPoland distributes premium hemp CBD oil in the EU. The company grows high quality, organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a planned capacity of 219,000 kgs and is building 1,643,600 sq. ft. of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark. For more information, visit the company’s website at www.TGOD.ca.

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, The Green Organic Dutchman Holdings Ltd. TGODF | Leave a comment

MissionIRNewsBreaks – TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) Appoints Ian Klassen to Board of Directors

TransCanna Holdings (CSE: TCAN) (FSE: TH8) this morning announced a new appointment to its board of directors. Ian Klassen joins the board and will additionally serve as chair of the company’s audit committee. Klassen brings nearly 30 years of experience in business management, public relations and government affairs to the company. His background includes serving as chief of staff to the Canadian Speaker of the House of Commons, as well as extensive experience in the administration of public companies, finance, government policy, media relationship strategies, business/government project management and legislative decision-making. “I would like to welcome Ian to our team,” TransCanna Director Stephen Giblin said in the news release. “He will be a valuable addition on multiple levels given his background and experience. A lot of work has gone into developing our financial model and strategic plan as we continue to build out our California based operations.”

To view the full press release, visit http://ibn.fm/rlO9C

About TransCanna Holdings Inc.

TransCanna Holdings is a Canadian-based company providing branding, transportation and distribution services, through its wholly owned California subsidiaries, to a range of industries including the cannabis marketplace. For more information, visit the company’s website at www.TransCanna.com.

NOTE TO INVESTORS: The latest news and updates relating to TCAN are available in the company’s newsroom at http://ibn.fm/TCAN

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, TransCanna Holdings Inc. TCAN | Leave a comment

MissionIRNewsBreaks – Canopy Rivers Inc.’s (TSX.V: RIV) (OTC: CNPOF) Portfolio Companies Enter Purchase and Supply Agreement, Demonstrate Thriving Ecosystem

Canopy Rivers (TSX.V: RIV) (OTC: CNPOF) this morning announced the entry of its portfolio companies, James E. Wagner Cultivation Corporation (“JWC”) (TSXV: JWCA) (OTCQX: JWCAF) and TerrAscend Corp. (CSE: TER) (OTCQX: TRSSF), into a purchase and supply agreement, demonstrating collaboration and synergy that is seen throughout the Canopy Rivers ecosystem. Under the agreement, JWC will supply cannabis flower and oils to TerrAscend, which will then be made available for purchase on TerrAscend’s online medical sales platform, Solace Health. The platform will provide JWC with exposure to thousands of registered medical patients across Canada. “The collaboration between JWC and TerrAscend is evidence of the Canopy Rivers ecosystem at work,” Canopy Rivers Chief Operating Officer Olivier Dufourmantelle said in the news release. “Portfolio companies that work together, thrive together. We are constantly striving to broker opportunities for synergy and collaboration within our portfolio.”

To view the full press release, visit http://ibn.fm/Ac7F8

About Canopy Rivers Inc.

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers identifies strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem. For more information, visit the company’s website at www.CanopyRivers.com.

NOTE TO INVESTORS: The latest news and updates relating to CNPOF are available in the company’s newsroom at http://ibn.fm/CNPOF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Canopy Rivers Inc. CNPOF, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Pressure BioSciences Inc. (PBIO) Releases Q2 2019 Financial Results, Provides Business Update

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced financial results for the second quarter ended June 30, 2019, provided a business update, and offered guidance for the remainder of the fiscal year and for FY 2020. In the update, the company reported 2019 second quarter highlights that include record consumables sales, strong growth in BaroFold and UST Services, and launch of a revolutionary CBD processing system. “Because of the poor water solubility of today’s oil-based CBD products, most ingested CBD is flushed from the body, leaving little of the product to provide its beneficial properties,” Pressure BioSciences President and CEO Richard T. Schumacher said in the news release. “After much diligence and analysis, we concluded that we have the expertise and experience to successfully address this critical issue. Consequently, we pulled significant hours away from many of our staff over the past few months and had them focus on the development of an instrument system – based on our patented UST platform – that would increase the water-solubility, and thus the absorption, of CBD Oil. We succeeded; the result of that success is the BaroShear K45 processing system.”

To view the full press release, visit http://ibn.fm/M9QEC

About Pressure BioSciences Inc.

Pressure BioSciences (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life-sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented-enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control biomolecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of the company’s pressure-based technologies in the following areas: (1) the use of its recently acquired PreEMT technology from BaroFold Inc. to allow entry into the biologics-contract, research-services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and (ii) prepare higher-quality, homogenized, extended shelf-life or room-temperature stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Pressure BioSciences Inc. PBIO | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Receives Four New Patents, Increasing Total Granted to 15

Biotechnology company and global drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced the granting of four of its pending patent applications via its wholly-owned subsidiary Poviva Corp. According to the update, the new patents cover delivery of cannabinoids such as THC and CBD, NSAIDs such as ibuprofen, nicotine, and vitamins. With issuance of these four patents, Lexaria’s total patents granted has increased to 15, with eight in the US and seven in Australia, and the company has roughly 60 patent applications pending throughout the world. Lexaria is one of the most patent-rich firms in the Western World for effective blood plasma delivery of cannabis-related compounds in the cannabis or hemp industries with 15 patents already granted for the delivery of cannabinoids.

To view the full press release, visit http://ibn.fm/Gpdjg

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH(TM) delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Youngevity International Inc. (NASDAQ: YGYI) Reports 2019 Q2 and Six Months Results, 21.2% Increase of Second Quarter Revenues

Youngevity International (NASDAQ: YGYI), a leading multi-channel lifestyle company operating in three distinct business segments, this morning reported financial results for the second quarter and six months ended June 30, 2019. Per the update, the company’s revenues for second quarter were $53.7 million compared to $44.3 million in the prior year, reflecting an increase of 21.2 percent. In addition, Youngevity’s gross profit for the second quarter improved to $25.9 million from $25.4 million in the prior year, and net loss improved to ($47,000) in the second quarter from ($614,000) in the prior year. “We are pleased with our quarter over quarter revenue growth and we are encouraged by the increase in gross profits and in Adjusted EBITDA over Q2 2018,” Steve Wallach, chairman and CEO of Youngevity International stated in the news release. “We are making progress toward stabilizing revenues in our direct selling segment and this combined with strong revenue delivered by our commercial coffee segment has provided our second consecutive quarter of Q over Q growth.”

To view the full press release, visit http://ibn.fm/lsUvQ

About Youngevity International Inc.

Youngevity International Inc. is a multi-channel lifestyle company operating in three distinct business segments, including a commercial coffee enterprise, a commercial hemp enterprise and a multi-vertical omni direct selling enterprise. The company features a multi country selling network and has assembled a virtual Main Street of products and services under one corporate entity; YGYI offers products from the six top-selling retail categories, including health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry and innovative services. For more information, visit the company’s website at www.YGYI.com.

NOTE TO INVESTORS: The latest news and updates relating to YGYI are available in the company’s newsroom at http://ibn.fm/YGYI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Youngevity International Inc. YGYI | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Appoints Consumer Packaged Goods Veteran to Board of Directors

Biotechnology company and global drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced the appointment of Brian Quigley to its board of directors. Quigley most recently spent 16 years at Altria Group, seven of which were spent as president and CEO for U.S. Smokeless Tobacco and Nu-Mark, Altria’s innovation company, during the time that the existing Lexaria and Altria business relationship was negotiated. Quigley is a 20-year Consumer Packaged Goods veteran with a background of managing complex regulatory environments including for novel and innovative nicotine products, and holds additional deep experience with operations and marketing. “Lexaria continues to build towards its role as one of the world’s leading reduced harm nicotine delivery companies and we welcome Brian’s expertise,” Lexaria Chairman of the Board Chris Bunka said in the news release. “His years of regulatory, product launch, and Fortune-500 corporate experience will be an invaluable asset to Lexaria as we expand our presence in reduced-harm nicotine products around the world.”

To view the full press release, visit http://ibn.fm/ZISzc

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH(TM) delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) Enters Definitive Agreement with SolDaze

TransCanna Holdings (CSE: TCAN) (FSE: TH8) this morning announced its entry into a definitive purchase agreement for all of the outstanding equity interest in Tres Ojos Naturals LLC, doing business as SolDaze, a Santa Cruz, California-based limited liability company. Per the update, the transaction will absorb SolDaze’s branding asset package into the company’s expanding asset portfolio, providing what it believes will be significant penetration into the cannabis market in California. “We are very pleased and excited to welcome the SolDaze team into the TransCanna family. We would like to recognize their efforts, achievements and in particular their patience and dedication to this process,” Transcanna President and Chair Arni Johannson said in the news release. “The SolDaze brand has a very bright future and with the support of TransCanna will be introducing a variety of new SKUs, including the much anticipated launch of ‘Spicy Mango’. The company is excited about the prospects of future growth that this acquisition will provide once consummated.”

To view the full press release, visit http://ibn.fm/MzKE8

About TransCanna Holdings Inc.

TransCanna Holdings is a Canadian-based company providing branding, transportation and distribution services, through its wholly owned California subsidiaries, to a range of industries including the cannabis marketplace. For more information, visit the company’s website at www.TransCanna.com.

NOTE TO INVESTORS: The latest news and updates relating to TCAN are available in the company’s newsroom at http://ibn.fm/TCAN

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, TransCanna Holdings Inc. TCAN | Leave a comment